PARIS, Feb. 10, 2014 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its development plan for the CE marking of NBTXR3, the first product from the NanoXray pipeline.
Help employers find you! Check out all the jobs and post your resume.
